Elovl6 promotes nonalcoholic steatohepatitis

Hepatology

Volumn 56, Issue 6, 2012, Pages 2199-2208

  Matsuzaka, Takashi ^a   Atsumi, Ayaka ^a   Matsumori, Rie ^a   Nie, Tang ^a   Shinozaki, Haruna ^a   Suzuki Kemuriyama, Noriko ^a   Kuba, Motoko ^a   Nakagawa, Yoshimi ^a   Ishii, Kiyoaki ^a   Shimada, Masako ^a   Kobayashi, Kazuto ^a   Yatoh, Shigeru ^a   Takahashi, Akimitsu ^a   Takekoshi, Kazuhiro ^a   Sone, Hirohito ^a   Yahagi, Naoya ^a   Suzuki, Hiroaki ^a   Murata, Soichiro ^b   Nakamuta, Makoto ^c   Yamada, Nobuhiro ^a   Shimano, Hitoshi ^a   more..

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; COLLAGEN TYPE 4; CRYOPYRIN; ELONGATION OF VERY LONG CHAIN FATTY ACID 6; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; PALMITIC ACID; PALMITOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FEMALE; GAIN OF FUNCTION MUTATION; GENE DELETION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEPATITIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID COMPOSITION; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

ACETYLTRANSFERASES; ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; CARRIER PROTEINS; CHOLESTEROL; DIET, ATHEROGENIC; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; INFLAMMASOMES; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OXIDATIVE STRESS; PALMITIC ACID; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 84870541988     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25932     Document Type: Article

References (28)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523.
2. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-348.
3. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. HEPATOLOGY 2007; 46: 582-589.
4. Matsuzaka T, Shimano H. Molecular mechanisms involved in hepatic steatosis and insulin resistance. J Diabetes Invest 2011; 2: 170-175.
5. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-531.
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. HEPATOLOGY 2010; 51: 1820-1832.
7. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
8. Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008; 19: 567-576.
9. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. HEPATOLOGY 2007; 46: 1081-1090.
10. Moon YA, Shah NA, Mohapatra S, Warrington JA, Horton JD. Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J Biol Chem 2001; 276: 45358-45366.
11. Matsuzaka T, Shimano H, Yahagi N, Yoshikawa T, Amemiya-Kudo M, Hasty AH, et al. Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. J Lipid Res 2002; 43: 911-920.
12. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007; 13: 1193-1202.
13. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. HEPATOLOGY 2007; 46: 1392-1403.
14. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 2011; 32: 373-379.
15. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012; 481: 278-286.
16. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
17. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. HEPATOLOGY 2011; 54: 133-144.
18. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375: 1634-1639.
19. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. HEPATOLOGY 2007; 45: 1366-1374.
20. Li ZZ, Berk M, McIntyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009; 284: 5637-5644.
21. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003; 100: 3077-3082.
22. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-287.
23. Han C, Li G, Lim K, DeFrances MC, Gandhi CR, Wu T. Transgenic expression of cyclooxygenase-2 in hepatocytes accelerates endotoxin-induced acute liver failure. J Immunol 2008; 181: 8027-8035.
24. Lopez-Parra M, Titos E, Horrillo R, Ferre N, Gonzalez-Periz A, Martinez-Clemente M, et al. Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res 2008; 49: 2513-2523.
25. Titos E, Ferre N, Lozano JJ, Horrillo R, Lopez-Parra M, Arroyo V, et al. Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. Prostaglandins Other Lipid Mediat 2010; 92: 54-61.
26. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007; 20: 351-358.
27. Morcillo S, Martin-Nunez GM, Rojo-Martinez G, Almaraz MC, Garcia-Escobar E, Mansego ML, et al. ELOVL6 genetic variation is related to insulin sensitivity: a new candidate gene in energy metabolism. PLoS One 2011; 6: e21198.
28. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010; 327: 296-300.